HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Traditional Chinese Medicine

923.715

-5.951-0.64%

Number of Gainers:2

Number of Losers:6

Number of Flat:3

PE:- -

High:930.753

Open:927.710

Low:918.611

Close:929.665

Volume:63.41M

Turnover:273.04M

Market Cap:94.17B

Float Cap:64.86B

Loading ...

LUYE PHARMA (02186) Issues 52.92 Million Shares Due to Convertible Bond Conversion

Consun Pharmaceutical Group Insider Ups Holding During Year

Simply Wall St.

Tong Ren Tang Chinese Medicine's Chair Retires; Successor Named

MT Newswires Live

TONGRENTANGCM (03613): Yan Han Appointed as Chairman of the Board

Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH): Ceftazidime for Injection Passes Generic Drug Consistency Evaluation

Baiyunshan Pharma Gets Nod to Make Amendments to Two Antibiotics

MT Newswires Live

China Traditional Chinese Medicine Holdings Signs New Contracts for Alcohol Extraction Workshop Construction

China Traditional Chinese Medicine - Unit Entered Alcohol Extraction Workshop Construction Project, Others

THOMSON REUTERS

China Traditional Chinese Medicine - Purification Engineering Construction Agreement Fee RMB16 Mln, Others

THOMSON REUTERS

TRAD CHI MED (00570) Reports Interim Results with Shareholders' Loss of RMB 108 Million, Turning from Profit to Loss Year-over-Year

BRIEF-China Traditional Chinese Medicine Posts HY Loss Attributable Of RMB107.9 MLN

PURAPHARM (01498): Hong Tingan Appointed as Independent Non-Executive Director

China Traditional Chinese Medicine Holdings H1 Revenue RMB 7,463.4 Million

THOMSON REUTERS

PuraPharm Corp. Ltd. Appoints Dr. Hung Ting On as Independent Non-Executive Director and Chairman of Audit Committee

MODERN CHI MED (01643) Reports Interim Results with Shareholders' Profit of RMB 2.5 Million, Turning from Loss to Profit Year-on-Year

Modern Chinese Medicine Group H1 Gross Margin 25%

THOMSON REUTERS

CONSUN PHARMA (01681) Target Price Raised to HK$15.9, Attractive Valuation and Dividend Yield

BAIYUNSHAN PH (00874): Subsidiary Baiyunshan Hanfang Receives Marketing Authorization for Structured Triglycerides Chemical Raw Material

Luye Pharma Group's H1 Profit Falls 19%

MT Newswires Live

LUYE PHARMA (02186) Reports Interim Results with Shareholders' Profit of RMB313 Million, Down 19.33% YoY

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1606/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","market":"HK","secType":"PLATE","nameCN":"Traditional Chinese Medicine","latestPrice":923.71454,"timestamp":1757405290965,"preClose":929.6653,"halted":0,"volume":63411925,"delay":0,"changeRate":-0.006401,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-5.950745,"latestTime":"09-09 16:00:00","open":927.7097,"high":930.7533,"low":918.61084,"amount":273041106,"amplitude":0.013061,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757467800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1757381400000,1757390400000],[1757394000000,1757404800000]],"pbRate":1.004763,"peRate":16.96827,"turnoverRate":0.003997,"increases":1,"decrements":7,"flats":3,"marketCap":94165439488,"floatMarketCap":64864115888},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","high":930.7533,"amplitude":0.013061,"preClose":929.6653,"low":918.61084,"pbRate":"1.004763","latestPrice":923.71454,"volume":63411925,"delay":0,"open":927.7097,"prevYearClose":739.0471,"prevWeekClose":922.771,"prevMonthClose":900.909,"prevQuarterClose":837.002,"fiveDayClose":904.764,"twentyDayClose":889.851,"sixtyDayClose":857.746,"secType":"PLATE","market":"HK","turnoverRate":0.003997,"peRate":16.96827,"marketCap":94165439488,"floatMarketCap":64864115888,"timestamp":1757405290965,"nameCN":"Traditional Chinese Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1606\",,,,undefined,":{"bkCode":"BK1606","up":2,"down":6,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1606\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1116172470","title":"LUYE PHARMA (02186) Issues 52.92 Million Shares Due to Convertible Bond Conversion","url":"https://stock-news.laohu8.com/highlight/detail?id=1116172470","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116172470?lang=en_us&edition=fundamental","pubTime":"2025-09-09 17:52","pubTimestamp":1757411548,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) announced that on September 9, 2025, the company issued 52.9194 million shares due to the conversion of convertible bonds.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1583","BK1191","02186"],"gpt_icon":0},{"id":"2565999518","title":"Consun Pharmaceutical Group Insider Ups Holding During Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2565999518","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565999518?lang=en_us&edition=fundamental","pubTime":"2025-09-06 08:09","pubTimestamp":1757117387,"startTime":"0","endTime":"0","summary":"Insiders were net buyers of Consun Pharmaceutical Group Limited's ( HKG:1681 ) stock during the past year. That is...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/consun-pharmaceutical-group-insider-ups-holding-during-year","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/consun-pharmaceutical-group-insider-ups-holding-during-year","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01681","BK1606","BK1191"],"gpt_icon":0},{"id":"2564837184","title":"Tong Ren Tang Chinese Medicine's Chair Retires; Successor Named","url":"https://stock-news.laohu8.com/highlight/detail?id=2564837184","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564837184?lang=en_us&edition=fundamental","pubTime":"2025-09-04 19:41","pubTimestamp":1756986082,"startTime":"0","endTime":"0","summary":"Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) chairman and an executive director, Gu Hai Ou, retired effective Thursday, a same-day Hong Kong bourse filing said.The firm named Executive Director Yan Han as its new chair effective the same day.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1606","BK1191","03613"],"gpt_icon":0},{"id":"1165815593","title":"TONGRENTANGCM (03613): Yan Han Appointed as Chairman of the Board","url":"https://stock-news.laohu8.com/highlight/detail?id=1165815593","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165815593?lang=en_us&edition=fundamental","pubTime":"2025-09-04 17:42","pubTimestamp":1756978962,"startTime":"0","endTime":"0","summary":"TONGRENTANGCM (03613) announced that Gu Haiou has resigned from his positions as executive director, chairman of the board, and authorized representative under Rule 3.05 of the Rules Governing the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613","BK1606","BK1191"],"gpt_icon":0},{"id":"1132935565","title":"Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH): Ceftazidime for Injection Passes Generic Drug Consistency Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=1132935565","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132935565?lang=en_us&edition=fundamental","pubTime":"2025-09-03 18:10","pubTimestamp":1756894227,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332.SH) announced that its controlling subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (\"Tianxin Pharmaceutical\"),...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00874","BK1521","BK0097","BK0196","BK0175","BK1197","BK1515","BK0096","BK0183","BK1191","BK1606","BK0239","BK0028","BK0012","BK0070","BK0188","600332"],"gpt_icon":0},{"id":"2564582465","title":"Baiyunshan Pharma Gets Nod to Make Amendments to Two Antibiotics","url":"https://stock-news.laohu8.com/highlight/detail?id=2564582465","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564582465?lang=en_us&edition=fundamental","pubTime":"2025-09-02 10:35","pubTimestamp":1756780547,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical Holdings  received approval from China's National Medical Products Administration to make changes to two antibiotics after passing the regulator's consistency evaluation, according to a Shanghai bourse filing on Tuesday.The pharmaceutical company will be able to change the drug quality standards and packaging of cefoperazone sodium and sulbactam sodium for injection and clindamycin phosphate injection, as well as the latter's formulation process.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0070","BK0183","BK0188","BK1521","600332","BK0097","BK0239","BK1191","BK1515","BK0012","BK0196","BK1606","BK0096","BK0028","BK1197","BK0175","00874"],"gpt_icon":0},{"id":"2564819843","title":"China Traditional Chinese Medicine Holdings Signs New Contracts for Alcohol Extraction Workshop Construction","url":"https://stock-news.laohu8.com/highlight/detail?id=2564819843","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564819843?lang=en_us&edition=fundamental","pubTime":"2025-09-01 18:36","pubTimestamp":1756723013,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings Co. Limited has announced the signing of new agreements related to the Alcohol Extraction Workshop Construction Project. On September 1, 2025, its subsidiary, Tongjitang Pharmaceutical, entered into contracts with Pharmengin and Wuhan Hongli. These agreements involve the construction of an alcohol extraction workshop and its associated facilities, covering a range of services including building decoration, water supply, drainage, heating, ventilation, electrical, and process piping engineering. The agreements are considered to be on normal commercial terms and are deemed fair and reasonable, aligning with the company's interests and those of its shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250901:nNDLfLm0m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1515","BK1606","00570"],"gpt_icon":0},{"id":"2564816043","title":"China Traditional Chinese Medicine - Unit Entered Alcohol Extraction Workshop Construction Project, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2564816043","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564816043?lang=en_us&edition=fundamental","pubTime":"2025-09-01 18:31","pubTimestamp":1756722682,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250901:nFWN3UN04W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1606","BK1515","BK1191","00570"],"gpt_icon":0},{"id":"2564160488","title":"China Traditional Chinese Medicine - Purification Engineering Construction Agreement Fee RMB16 Mln, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2564160488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564160488?lang=en_us&edition=fundamental","pubTime":"2025-09-01 18:31","pubTimestamp":1756722682,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250901:nFWN3UN04W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1606","00570","BK1515"],"gpt_icon":0},{"id":"1123474853","title":"TRAD CHI MED (00570) Reports Interim Results with Shareholders' Loss of RMB 108 Million, Turning from Profit to Loss Year-over-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1123474853","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123474853?lang=en_us&edition=fundamental","pubTime":"2025-08-29 22:26","pubTimestamp":1756477579,"startTime":"0","endTime":"0","summary":"TRAD CHI MED (00570) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 7.463 billion, representing an 11% decrease year-over-year. Shareholders'...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","00570","BK1191","BK1515"],"gpt_icon":0},{"id":"2563029089","title":"BRIEF-China Traditional Chinese Medicine Posts HY Loss Attributable Of RMB107.9 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2563029089","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563029089?lang=en_us&edition=fundamental","pubTime":"2025-08-29 21:45","pubTimestamp":1756475101,"startTime":"0","endTime":"0","summary":"BRIEF-China Traditional Chinese Medicine Posts HY Loss Attributable Of RMB107.9 MLNAug 29  - China Traditional Chinese Medicine Holdings Co Ltd 0570.HK:CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS H1 REVENUE RMB 7,463.4 MILLIONHY LOSS ATTRIBUTABLE RMB107.9 MILLIONFurther company coverage: 0570.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nPLX051AF7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1515","00570","BK1191"],"gpt_icon":0},{"id":"1125741244","title":"PURAPHARM (01498): Hong Tingan Appointed as Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1125741244","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125741244?lang=en_us&edition=fundamental","pubTime":"2025-08-29 21:40","pubTimestamp":1756474826,"startTime":"0","endTime":"0","summary":"PURAPHARM (01498) announced that Dr. Hong Tingan has been appointed as independent non-executive director, chairman of the board audit committee, member of the board remuneration committee, and member of the board nomination committee, effective from August 29, 2025.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1191","01498"],"gpt_icon":0},{"id":"2563260150","title":"China Traditional Chinese Medicine Holdings H1 Revenue RMB 7,463.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2563260150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563260150?lang=en_us&edition=fundamental","pubTime":"2025-08-29 21:22","pubTimestamp":1756473769,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nPLX051AF7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","00570","BK1606","BK1515"],"gpt_icon":0},{"id":"2563116025","title":"PuraPharm Corp. Ltd. Appoints Dr. Hung Ting On as Independent Non-Executive Director and Chairman of Audit Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2563116025","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563116025?lang=en_us&edition=fundamental","pubTime":"2025-08-29 20:57","pubTimestamp":1756472250,"startTime":"0","endTime":"0","summary":"PuraPharm Corporation Limited has announced the appointment of Dr. Hung Ting On, John as an independent non-executive director. Dr. Hung will also serve as the chairman of the audit committee, and as a member of both the remuneration and nomination committees. This appointment took effect on August 29, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PuraPharm Corp. Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL38Q2yB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01498","BK1191","BK1606"],"gpt_icon":0},{"id":"1137861261","title":"MODERN CHI MED (01643) Reports Interim Results with Shareholders' Profit of RMB 2.5 Million, Turning from Loss to Profit Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1137861261","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137861261?lang=en_us&edition=fundamental","pubTime":"2025-08-29 19:43","pubTimestamp":1756467820,"startTime":"0","endTime":"0","summary":"MODERN CHI MED (01643) announced its results for the six months ended June 30, 2025. The group recorded revenue of RMB 64.8 million during the period, representing a decrease of 15.4% year-on-year....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01643","BK1191","BK1606"],"gpt_icon":0},{"id":"2563042067","title":"Modern Chinese Medicine Group H1 Gross Margin 25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563042067","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563042067?lang=en_us&edition=fundamental","pubTime":"2025-08-29 19:23","pubTimestamp":1756466617,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nPLX123349:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1606","01643","BK1191"],"gpt_icon":0},{"id":"1100085768","title":"CONSUN PHARMA (01681) Target Price Raised to HK$15.9, Attractive Valuation and Dividend Yield","url":"https://stock-news.laohu8.com/highlight/detail?id=1100085768","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100085768?lang=en_us&edition=fundamental","pubTime":"2025-08-29 17:42","pubTimestamp":1756460527,"startTime":"0","endTime":"0","summary":"A research report maintains a \"Buy\" rating on CONSUN PHARMA (01681), raising the target price from HK$13.9 to HK$15.9, citing the stock's low valuation and attractive dividend yield. The firm...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06099","BK1191","01681","BK1606","BK1564","BK1147"],"gpt_icon":0},{"id":"1194962127","title":"BAIYUNSHAN PH (00874): Subsidiary Baiyunshan Hanfang Receives Marketing Authorization for Structured Triglycerides Chemical Raw Material","url":"https://stock-news.laohu8.com/highlight/detail?id=1194962127","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194962127?lang=en_us&edition=fundamental","pubTime":"2025-08-29 17:20","pubTimestamp":1756459257,"startTime":"0","endTime":"0","summary":"BAIYUNSHAN PH (00874) announced that its subsidiary Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. (\"Baiyunshan Hanfang\") has recently received the Marketing Authorization Approval...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0070","BK0183","BK0196","BK0175","00874","BK1191","600332","BK0096","BK0239","BK1606","BK0188","BK1197","BK0028","BK0097","BK1521","BK1515"],"gpt_icon":0},{"id":"2563010636","title":"Luye Pharma Group's H1 Profit Falls 19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563010636","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563010636?lang=en_us&edition=fundamental","pubTime":"2025-08-29 16:54","pubTimestamp":1756457647,"startTime":"0","endTime":"0","summary":"Luye Pharma Group  reported 312.9 million yuan in attributable profit for the first half of 2025, falling 19% from 387.8 million yuan a year earlier, according to a Hong Kong bourse filing Thursday.Earnings per share was 0.0832 yuan, compared with 0.1031 yuan in the prior year.Revenue rose 3.5% year-on-year to 3.18 billion yuan, figures showed.Shares of the pharma company gained 8.1% in afternoon trade Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1606","BK1191","BK1583","02186"],"gpt_icon":0},{"id":"1136684728","title":"LUYE PHARMA (02186) Reports Interim Results with Shareholders' Profit of RMB313 Million, Down 19.33% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=1136684728","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136684728?lang=en_us&edition=fundamental","pubTime":"2025-08-28 23:01","pubTimestamp":1756393282,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB3.181 billion, representing a year-over-year increase of 3.46%. Profit attributable...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1606","02186","BK1583"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}]}}